Physician profile
Virendra Patel
NPI 1508807082
$6,824.48
in general payments reported to CMS, 2019-2025
41 companies · $999 in 2025
The $999 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $405 · 2021: $825 · 2022: $813 · 2023: $1,170 · 2024: $1,416 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,584.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $774.31 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $710.06 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $655.87 | 2019-2025 | |
| Pfizer INC. | $529.82 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $523.21 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $477.19 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Merck Sharp & Dohme LLC | $332.55 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.86 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $236.85 | 2019-2023 | |
| Abiomed | $221.00 | 2023-2025 | Impella |
| Abbott Laboratories | $220.92 | 2019-2025 | Aveir |
| Astrazeneca Pharmaceuticals Lp | $216.42 | 2019-2025 | Farxiga, Lynparza |
| Amarin Pharma, INC. | $171.59 | 2019-2022 | |
| Allergan, INC. | $123.50 | 2019 | |
| Neurelis, INC. | $120.58 | 2024 | Valtoco |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virendra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.